An epidemic cluster of pneumonia cases caused by the novel coronavirus, SARS-CoV-2, first broke out in Wuhan City, China in December 2019. 1 This infection, named COVID-19, then spread rapidly throughout continents and was declared pandemic on March 11, 2020. Currently, there are only anecdotal reports of COVID-19 in immunosuppressed children 2-4 or in pediatric patients with cancer, and

Background There are few data on the mechanism of recurrent neurological events after transcatheter closure of patent foramen ovale (PFO) in cryptogenic stroke or TIA. Methods We retrospectively reviewed PFO closure procedures for the secondary prevention of cryptogenic stroke/TIA performed between 1999 and 2014 in Bologna, Italy. Results Written questionnaires were completed by 402 patients. Mean follow-up was 7 ± 3 years. Stroke recurred in 3.2% (0.5/100 patients-year) and TIA in 2.7% (0.4/100 patients-year). Ninety-two percent of recurrent strokes were not cryptogenic. Recurrent stroke was noncardioembolic in 69% of patients, AF related in 15% of patients, device related in 1 patient, and cryptogenic in 1 patient. AF was diagnosed after the procedure in 21 patients (5.2%). Multivariate Cox's proportion hazard model identified age ≥ 55 years at the time of closure (OR 3.16, p=0.007) and RoPE score < 7 (OR 3.21, p=0.03) as predictors of recurrent neurological events. Conclusion Recurrent neurological events after PFO closure are rare, usually noncryptogenic and associated with conventional vascular risk factors or AF related. Patients older than 55 years of age and those with a RoPE score < 7 are likely to get less benefit from PFO closure. After transcatheter PFO closure, lifelong strict vascular risk factor control is warranted.

phenotype of cancer-associated fibroblast (CAF). Mature (thin, wavy, and small spindle-shaped fibroblasts) and immature (large, plump spindleshaped with prominent nucleoli) groups were categorized by using cutoff 50%. Results: Total 59 LAHC patients with qualified paired CT images were subjected to delta-radiomic analysis. The median follow-up time was 33.5 (IQR 17.9-74.0) months. A model including 5 radiomic features from delta-GTV to predict better PFS of patients receiving subsequent CCRT was established (likelihood ratio test p < 0.05; Table). R score was validated with all dataset (area under the curve Z 0.74). Low R score (<-0.34), but not volume changes of GTVs, was associated with better PFS in both univariate (p < 0.05) and multivariate (p < 0.05) analysis. In TME assessment, the histological phenotype of mature CAF, but not tumor infiltrating lymphocyte, correlated with better PFS. Low R score correlated with mature CAF category (positive and negative predictive values: 100% and 75%, respectively), implying CAF as a putative biological rationale behind delta-radiomics. Conclusion: The established model for TME from radiomic features of delta-GTV after IC might be a potential imaging biomarker to predict clinical outcome of subsequent CCRT in LAHC. Phenotype of CAF in TME may correlate with radiomic alterations and clinical outcome.